Net Income

With a $140M war chest, Empower Semiconductor expands to Silicon Valley and Munich, betting its vertical power tech can solve the energy crisis facing AI.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A landmark private equity deal in Europe's produce sector is about more than money; it's a strategic move to build a resilient food supply chain.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

With a critical $1.74M lifeline, Northstar Clean Technologies is racing to prove its shingle recycling tech can be a profitable circular economy champion.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.

Reborn Coffee touts a tech-driven global expansion, but a looming Nasdaq delisting and deep financial losses paint a much more complicated picture.

As restaurants face economic headwinds, a new AI platform is empowering servers, enhancing guest experience, and promising to double bottom-line profits.

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.

A massive 320 MWh battery project in Belgium reveals how strategic investments in energy storage are becoming the ultimate luxury: grid stability and sustainability.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?